Global Chemotherapy Induced Neutropenia (CIN) Market Explored by DelveInsight in Its New Report Recently Added at MarketPublishers.com
04 Apr 2017 • by Natalie Aster
LONDON – Neupogen (Filgrastim), manufactured and sold by Amgen is the 1st G-CSF approved for chemotherapy induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was approved later in 2002. At present, Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) capture the major chunk of the overall CIN market size. Furthermore, novel chemical entities are predicted to launch in the years ahead.
The value of the world’s CIN market stood at around USD 3.67 billion as of 2016.
The cutting-edge research study “Chemotherapy Induced Neutropenia (CIN) -Market Insights, Epidemiology and Market Forecast-2023” elaborated by DelveInsight offers a detailed over view of the disease as well as provides a granular analysis of the market scenario at the global scale and across the 7 major markets, including Japan, the US, Germany, France, Spain, the UK, Italy. It covers the CIN therapeutics landscape, reviews the existing treatment practices as well as offers reliable statistics (historical, present and forecast).
The study highlights therapeutic scenario and patients for 10 major cancer indications (prostate cancer, breast cancer, leukemia, cervical cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, non-hodgkin lymphoma), which present a risk of developing CIN as an adverse event of the chemotherapies of respective cancers.
Follow to the DelveInsight catalogue at MarketPublishers.com to find many other research studies by this publisher.